Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

11.63 +0.27 (+2.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Expands Biosimulation Market with AI-Driven QSP Platform
Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies 
From Certara
Via GlobeNewswire
Certara Scientists are Among the Topmost Cited Biopharma Researchers
Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 
From Certara
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 5, 2025
 
Via Benzinga
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
From Certara
Via GlobeNewswire
Beyond The Numbers: 4 Analysts Discuss Certara Stock
 
Via Benzinga
RH Posts Downbeat Results, Joins Frequency Electronics, Tronox And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
Solution delivers a 50% reduction in time spent drafting mapping specifications, according to internal measurements 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara (CERT) Q2 Revenue Jumps 12%
Via The Motley Fool
Topics Artificial Intelligence
Certara Reports Second Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
From Certara
Via GlobeNewswire
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development 
From Certara
Via GlobeNewswire
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
From Certara
Via GlobeNewswire
Certara Announces Expansion of Clinical Technology Collaboration with Merck
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality 
From Certara
Via GlobeNewswire
What Analysts Are Saying About Certara Stock
 
Via Benzinga
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Via The Motley Fool
Topics Artificial Intelligence
Certara Reports First Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
3 Momentum Stocks That Could Soar Post-Market Volatility
Three unexpected companies have rallied quickly in the period following tariff-related market turbulence; can they maintain momentum? 
Via MarketBeat
Topics Artificial Intelligence World Trade
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion... 
Via Benzinga
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
Top 3 Health Care Stocks You May Want To Dump This Quarter
 
Via Benzinga
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
Certara reports $106M Q1 revenue, authorizes $100M buyback, and launches a new AI-driven non-animal testing tool to support biopharma innovation. 
Via Benzinga
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies 
From Certara
Via GlobeNewswire
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization
From Certara
Via GlobeNewswire
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty. 
Via Benzinga
What Analysts Are Saying About Certara Stock
 
Via Benzinga
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency. 
Via Benzinga
Topics Animal Testing Artificial Intelligence
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.